New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

1

What Lonza’s $1.2B buy of Roche biologics plant means for CDMO market

Last week, Swiss contract manufacturer Lonza announced it was paying $1.2 billion to buy a Roche manufacturing facility in Vacaville, California. The deal is meant to boost Lonza’s production of commercial mammalian products, which are made from cells isolated from animal tissues, and to expand its U.S. manufacturing footprint. The acquisition is indicative of the growing reliance of biopharma companies on contract manufacturers for biologics.